257 related articles for article (PubMed ID: 20638755)
1. Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay.
Al-Sha'er MA; Taha MO
Eur J Med Chem; 2010 Sep; 45(9):4316-30. PubMed ID: 20638755
[TBL] [Abstract][Full Text] [Related]
2. Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration.
Abu Khalaf R; Abu Sheikha G; Bustanji Y; Taha MO
Eur J Med Chem; 2010 Apr; 45(4):1598-617. PubMed ID: 20116902
[TBL] [Abstract][Full Text] [Related]
3. Ligand-based modelling followed by synthetic exploration unveil novel glycogen phosphorylase inhibitory leads.
Habash M; Taha MO
Bioorg Med Chem; 2011 Aug; 19(16):4746-71. PubMed ID: 21788139
[TBL] [Abstract][Full Text] [Related]
4. Elaborate ligand-based modeling and subsequent synthetic exploration unveil new nanomolar Ca2+/calmodulin-dependent protein kinase II inhibitory leads.
Shahin R; Taha MO
Bioorg Med Chem; 2012 Jan; 20(1):377-400. PubMed ID: 22112539
[TBL] [Abstract][Full Text] [Related]
5. Discovery of new renin inhibitory leads via sequential pharmacophore modeling, QSAR analysis, in silico screening and in vitro evaluation.
Al-Nadaf AH; Taha MO
J Mol Graph Model; 2011 Apr; 29(6):843-64. PubMed ID: 21376648
[TBL] [Abstract][Full Text] [Related]
6. Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors.
Taha MO; Dahabiyeh LA; Bustanji Y; Zalloum H; Saleh S
J Med Chem; 2008 Oct; 51(20):6478-94. PubMed ID: 18808096
[TBL] [Abstract][Full Text] [Related]
7. Ligand-based modeling followed by in vitro bioassay yielded new potent glucokinase activators.
Taha MO; Habash M; Hatmal MM; Abdelazeem AH; Qandil A
J Mol Graph Model; 2015 Mar; 56():91-102. PubMed ID: 25574766
[TBL] [Abstract][Full Text] [Related]
8. Discovery of cyclin-dependent kinase inhibitor, CR229, using structurebased drug screening.
Kim MK; Min J; Choi BY; Lim H; Cho YH; Lee CH
J Microbiol Biotechnol; 2007 Oct; 17(10):1712-6. PubMed ID: 18156791
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors.
Abu Hammad AM; Taha MO
J Chem Inf Model; 2009 Apr; 49(4):978-96. PubMed ID: 19341295
[TBL] [Abstract][Full Text] [Related]
11. Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening.
Al-Masri IM; Mohammad MK; Taha MO
ChemMedChem; 2008 Nov; 3(11):1763-79. PubMed ID: 18989859
[TBL] [Abstract][Full Text] [Related]
12. Development of novel 3D-QSAR combination approach for screening and optimizing B-Raf inhibitors in silico.
Shih KC; Lin CY; Zhou J; Chi HC; Chen TS; Wang CC; Tseng HW; Tang CY
J Chem Inf Model; 2011 Feb; 51(2):398-407. PubMed ID: 21182293
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore identification, docking and "in silico" screening for novel CDK1 inhibitors.
Dong X; Yan J; Du L; Wu P; Huang S; Liu T; Hu Y
J Mol Graph Model; 2012 Jul; 37():77-86. PubMed ID: 22622012
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel protein kinase B inhibitor by structure-based virtual screening.
Medina-Franco JL; Giulianotti MA; Yu Y; Shen L; Yao L; Singh N
Bioorg Med Chem Lett; 2009 Aug; 19(16):4634-8. PubMed ID: 19604696
[TBL] [Abstract][Full Text] [Related]
15. Application of Free-Wilson selectivity analysis for combinatorial library design.
Sciabola S; Stanton RV; Johnson TL; Xi H
Methods Mol Biol; 2011; 685():91-109. PubMed ID: 20981520
[TBL] [Abstract][Full Text] [Related]
16. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors.
Vyas VK; Ghate M; Goel A
J Mol Graph Model; 2013 May; 42():17-25. PubMed ID: 23507201
[TBL] [Abstract][Full Text] [Related]
17. Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening.
Taha MO; Atallah N; Al-Bakri AG; Paradis-Bleau C; Zalloum H; Younis KS; Levesque RC
Bioorg Med Chem; 2008 Feb; 16(3):1218-35. PubMed ID: 17988876
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors.
Huang S; Li R; Connolly PJ; Emanuel S; Middleton SA
Bioorg Med Chem Lett; 2006 Sep; 16(18):4818-21. PubMed ID: 16870444
[TBL] [Abstract][Full Text] [Related]
19. Multiple pharmacophore models combined with molecular docking: a reliable way for efficiently identifying novel PDE4 inhibitors with high structural diversity.
Chen Z; Tian G; Wang Z; Jiang H; Shen J; Zhu W
J Chem Inf Model; 2010 Apr; 50(4):615-25. PubMed ID: 20353193
[TBL] [Abstract][Full Text] [Related]
20. Structure-aided optimization of kinase inhibitors derived from alsterpaullone.
Kunick C; Zeng Z; Gussio R; Zaharevitz D; Leost M; Totzke F; Schächtele C; Kubbutat MH; Meijer L; Lemcke T
Chembiochem; 2005 Mar; 6(3):541-9. PubMed ID: 15696597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
